Giant Biogene (02367) fell more than 3% in late trading. As of press time, the stock was down 3.52% at HK$19.74, with turnover of HK$55.4758 million.
On the news front, on November 12, MSCI announced the results of its quarterly index review for November 2026, which will take effect after the close on November 30. A total of 38 stocks, including Giant Biogene, were removed from the MSCI China Index.
In addition, data from the first phase of Double 11 showed that GMV for the cosmetics category rose 5% year-on-year, outperforming the broader market's 2% growth, but slowing markedly compared with this year's 618, and was mainly driven by platform discounts and top KOLs.
CMB International said in a research report that Giant Biogene's growth turned clearly negative, falling 7.0% year-on-year in October, compared with 14.0% growth in September, mainly dragged down by Comfy and the Taotian channel.
Comments